Resumen de acción 1672 Ascletis Pharma Inc, empresa de biotecnología, se dedica a la investigación y desarrollo, fabricación, comercialización y venta de productos farmacéuticos en China continental. Saber más
Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Ascletis Pharma Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Ascletis Pharma Precios históricos de las acciones Precio actual de la acción HK$3.12 Máximo en las últimas 52 semanas HK$3.22 Mínimo de 52 semanas HK$0.76 Beta 0.58 Cambio en 1 mes 95.00% Variación en 3 meses 186.24% Cambio de 1 año 113.70% Variación en 3 años 1.96% Variación en 5 años 4.70% Variación desde la OPV -77.71%
Noticias y actualizaciones recientes
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
New major risk - Revenue and earnings growth Oct 14
Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans? Oct 07
Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F Oct 07
Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity Sep 17
New minor risk - Revenue size Sep 06 Ver más actualizaciones
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
New major risk - Revenue and earnings growth Oct 14
Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans? Oct 07
Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F Oct 07
Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity Sep 17
New minor risk - Revenue size Sep 06
New minor risk - Share price stability Aug 29
Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024 Jul 30
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024 Jun 13
Ascletis Pharma Inc., Annual General Meeting, May 23, 2024 Apr 28
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 Apr 03
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 26
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting Mar 11
Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024 Feb 24
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne Jan 24
New major risk - Revenue and earnings growth Jan 09
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis Jan 02
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate Dec 19
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne Dec 05
First half 2023 earnings: EPS exceeds analyst expectations Sep 30
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 29
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma Sep 27
Consensus revenue estimates decrease by 19%, EPS upgraded Aug 29
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely Aug 23
First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022) Aug 23
New major risk - Revenue and earnings growth Aug 23
Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023 Jul 24
Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis Jul 22
New minor risk - Profitability Jul 19
Consensus revenue estimates decrease by 22%, EPS upgraded Jul 19
Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023 Jun 06
Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection May 09
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 21
Forecast breakeven date moved forward to 2023 Mar 21
Consensus revenue estimates decrease by 12% Feb 25
Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B Feb 17
Consensus revenue estimates increase by 27% Feb 14
Forecast breakeven date moved forward to 2023 Feb 14
Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection Feb 01
Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa Jan 27
Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19 Jan 17
Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc Jan 03
Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19 Dec 13
Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA Dec 08
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne Dec 02
Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA Nov 30
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA Nov 24
Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA Nov 18
Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA Nov 16
Insufficient new directors Nov 16
Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022 Nov 07
What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today Nov 03
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Nov 03
Consensus revenue estimates fall by 19% Nov 01
Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication Oct 27
Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth Oct 13
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19 Oct 11
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash Oct 06
Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 28
Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22 Sep 16
Consensus revenue estimates fall by 13% Aug 29
Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates Aug 24
First half 2022 earnings released: CN¥0.081 loss per share (vs CN¥0.10 loss in 1H 2021) Aug 23
Ascletis Pharma Inc. Announces Change of Company Secretary Aug 23
Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA Aug 22
Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis Aug 17
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors Aug 08
Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA Aug 05
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients Aug 04
Ascletis Pharma Inc. to Report First Half, 2022 Results on Aug 22, 2022 Jul 28
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19 Jul 07
Ascletis Pharma Inc. Announces Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection Jul 05
Ascletis Pharma Inc. Announces First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection Jun 29
Ascletis Pharma Inc. Announces the Latest Phase Iib Clinical Trial Results of Subcutaneous Pd-L1 Antibody Asc22 (Envafolimab) in Patients with Chronic Hepatitis B (Chb) At an Oral Parallel Session of the International Liver Congress™ 2022 Jun 28
Ascletis Pharma Inc. Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022 Jun 16
Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer Jun 13
Ascletis Pharma Inc., Annual General Meeting, Jun 16, 2022 May 25
Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation May 19 Ascletis Pharma Inc. Announces Approval of Investigational New Drug Application
Forecast to breakeven in 2023 Apr 27
Insufficient new directors Apr 27
Ascletis Pharma Inc. Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 Apr 20
Ascletis Pharma Inc. Receives Approval for Investigational New Drug Application by China National Medical Products Administration Apr 07
Ascletis Pharma Inc. Completes Patient Enrollment in Phase II Clinical Trial of ASC42 for Chronic Hepatitis B Indication Mar 31
Consensus revenue estimates increase by 54% Mar 28
Ascletis Pharma Inc. Announces the Latest Results of Preclinical Studies of Two Novel Anti-Cancer Drug Candidates,ASC61 and ASC60, to Be Presented At AACR Annual Meeting 2022 Mar 28
Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts Mar 27
Ascletis Pharma Inc. to Report Fiscal Year 2021 Results on Mar 21, 2022 Mar 04
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Mar 01
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Feb 28
Ascletis Pharma Inc Announces Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients Feb 15
Ascletis Pharma Inc. Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant Feb 08
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely Feb 08
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors Feb 07
Ascletis Pharma Inc. Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA Jan 27
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma Jan 24
Consensus forecasts updated Jan 20
Ascletis Pharma Inc. Announces U.S. Ind Approval of Asc22, A Subcutaneously Administered Pd-L1 Antibody for Functional Cure of Chronic Hepatitis B Jan 18 Rentabilidad de los accionistas 1672 HK Biotechs Mercado HK 7D 26.8% -2.7% 1.5% 1Y 113.7% -9.2% 20.6%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: 1672 superó a la industria Hong Kong Biotechs, que obtuvo un rendimiento del -9.2% el año pasado.
Rentabilidad vs. Mercado: 1672 superó al mercado Hong Kong, que obtuvo un rendimiento del 20.6% el año pasado.
Volatilidad de los precios Is 1672's price volatile compared to industry and market? 1672 volatility 1672 Average Weekly Movement 12.8% Biotechs Industry Average Movement 11.5% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.0%
Precio estable de las acciones: 1672 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 1672 (13%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Ascletis Pharma Inc, empresa de biotecnología, se dedica a la investigación y desarrollo, fabricación, comercialización y venta de productos farmacéuticos en China continental. La empresa ofrece la tableta Ritonavir; y ASCLEVIR y GANOVO para el tratamiento del virus de la hepatitis C. También está desarrollando ASC22 para el tratamiento de la CHB y la cura funcional del VIH; ASC10 para el virus respiratorio sincitial; ASC10 y ASC11 para el tratamiento de COVID-19; ASC40, ASC41, ASC42, ASC43F FDC para la esteatohepatitis no alcohólica; y ASC42 para el tratamiento de la colangitis biliar primaria. Además, la empresa está desarrollando ASC40 para tratar el glioblastoma recurrente; ASC61 para tumores sólidos avanzados; y ASC40, una pequeña molécula oral para el tratamiento del acné.
Mostrar más Resumen de fundamentos de Ascletis Pharma Inc. ¿Cómo se comparan los beneficios e ingresos de Ascletis Pharma con su capitalización de mercado? Estadísticas fundamentales de 1672 Capitalización bursátil HK$3.02b Beneficios(TTM ) -HK$275.10m Ingresos (TTM ) HK$10.74m
281.2x Ratio precio-ventas (PS)
-11.0x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 1672 Ingresos CN¥10.09m Coste de los ingresos CN¥22.72m Beneficio bruto -CN¥12.63m Otros gastos CN¥245.84m Beneficios -CN¥258.47m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.27 Margen bruto -125.17% Margen de beneficio neto -2,561.68% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado 1672 a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/26 15:59 Precio de las acciones al final del día 2024/12/24 00:00 Beneficios 2024/06/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Ascletis Pharma Inc. está cubierta por 7 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Ling Zhang China Merchants Securities (HK) Co., Ltd Mingrui Wang Everbright Securities Co. Ltd. Siao Ye Everbright Securities Co. Ltd.
Mostrar 4 más analistas 
